Search results
Results from the WOW.Com Content Network
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares ...
What: Shareholders of generic-drug maker Impax. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...
Shares of Impax Laboratories spiraled down more than 25% today after the company reported that the FDA continues to have concerns with one of its manufacturing facilities. This issue has already ...
Impax Laboratories (NAS: IPXL) reported earnings yesterday. Here are the numbers you need to know. The 10-second takeawayFor the quarter ended March 31 (Q1), Impax Laboratories whiffed on revenues ...
The company's predecessor entity, privately held Impax Pharmaceuticals, Inc., was founded in 1995. Publicly traded Global Pharmaceutical Corporation and Impax Pharmaceuticals, Inc. completed a reverse merger, forming Impax Laboratories, Inc. on December 14, 1999. [18]
Impax Laboratories (NAS: IPXL) reported earnings on May 1. Here are the numbers you need to know. The 10-second takeaway For the quarter ended March 31 (Q1), Impax Laboratories beat expectations ...
Impax Laboratories (NAS: IPXL) reported earnings on Thursday. Here are the numbers you need to know. The 10-second takeawayFor the quarter ended June 30 (Q2), Impax Laboratories beat expectations ...
Impax Laboratories will release its quarterly report in early November, and investors are bracing themselves for the pharmaceutical company to post a loss, reversing a year-ago profit. But even ...